{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:56:14Z","timestamp":1792601774358,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008741","name":"European League Against Rheumatism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000960","name":"American College of Rheumatology Research and Education Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.tips.2025.06.005","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T04:10:43Z","timestamp":1752811843000},"page":"771-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Design and development of glucocorticoid receptor modulators"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-4306","authenticated-orcid":false,"given":"Christian","family":"Elling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8522-5047","authenticated-orcid":false,"given":"Florian","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.06.005_bb0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","article-title":"Views on glucocorticoid therapy in rheumatology: the age of convergence","volume":"16","author":"Buttgereit","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2025.06.005_bb0010","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.abd.2023.05.005","article-title":"Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know","volume":"99","author":"Tavares","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.tips.2025.06.005_bb0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.tips.2025.06.005_bb0020","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","article-title":"Glucocorticoids-all-rounders tackling the versatile players of the immune system","volume":"10","author":"Strehl","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2025.06.005_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41422-024-01016-0","article-title":"Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss","volume":"35","author":"Fu","year":"2025","journal-title":"Cell Res."},{"key":"10.1016\/j.tips.2025.06.005_bb0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.18632\/oncotarget.28191","article-title":"The long winding road to the safer glucocorticoid receptor (GR) targeting therapies","volume":"13","author":"Lesovaya","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.tips.2025.06.005_bb0035","doi-asserted-by":"crossref","first-page":"8393","DOI":"10.1093\/nar\/gkaa565","article-title":"Anti-inflammatory functions of the glucocorticoid receptor require DNA binding","volume":"48","author":"Escoter-Torres","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2025.06.005_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105334","article-title":"Dimerization of glucocorticoid receptors and its role in inflammation and immune responses","volume":"166","author":"Yang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2025.06.005_bb0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41586-024-07282-7","article-title":"Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids","volume":"629","author":"Auger","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.06.005_bb0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2025.06.005_bb0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41423-020-00526-2","article-title":"New insights into the cell- and tissue-specificity of glucocorticoid actions","volume":"18","author":"Quatrini","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.tips.2025.06.005_bb0060","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0140-6736(05)17989-6","article-title":"Optimised glucocorticoid therapy: the sharpening of an old spear","volume":"365","author":"Buttgereit","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2025.06.005_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.933676","article-title":"The role of conformational dynamics and allostery in the control of distinct efficacies of agonists to the glucocorticoid receptor","volume":"9","author":"Shi","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.tips.2025.06.005_bb0070","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.tips.2025.06.005_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","article-title":"Vamorolone: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2025.06.005_bb0080","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1152\/physiolgenomics.00134.2017","article-title":"Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone","volume":"50","author":"Fiorillo","year":"2018","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.tips.2025.06.005_bb0085","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/emmm.201302621","article-title":"VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects","volume":"5","author":"Heier","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.tips.2025.06.005_bb0090","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","article-title":"VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid","volume":"21","author":"Reeves","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2025.06.005_bb0095","doi-asserted-by":"crossref","first-page":"24285","DOI":"10.1073\/pnas.2006890117","article-title":"Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment","volume":"117","author":"Liu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.06.005_bb0100","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1016\/j.bmcl.2012.10.074","article-title":"Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat","volume":"22","author":"Hunt","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2025.06.005_bb0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jsbmb.2014.02.007","article-title":"The selective glucocorticoid receptor modulator CORT108297 restores faulty hippocampal parameters in Wobbler and corticosterone-treated mice","volume":"143","author":"Meyer","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.tips.2025.06.005_bb0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ando.2018.03.004","article-title":"Glucocorticoid receptor modulators","volume":"79","author":"Meijer","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.tips.2025.06.005_bb0115","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/JCP.0000000000001470","article-title":"Effect of miricorilant, a selective glucocorticoid receptor modulator, on olanzapine-associated weight gain in healthy subjects: a proof-of-concept study","volume":"41","author":"Hunt","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.tips.2025.06.005_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb5277","article-title":"Dynamic allosteric communication pathway directing differential activation of the glucocorticoid receptor","volume":"6","author":"K\u00f6hler","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tips.2025.06.005_bb0125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41594-022-00914-4","article-title":"Quaternary glucocorticoid receptor structure highlights allosteric interdomain communication","volume":"30","author":"Postel","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.tips.2025.06.005_bb0130","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1038\/s41401-021-00855-6","article-title":"Discovery of a novel nonsteroidal selective glucocorticoid receptor modulator by virtual screening and bioassays","volume":"43","author":"Pang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.tips.2025.06.005_bb0135","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.3390\/ijms22094747","article-title":"Rapid screening of glucocorticoid receptor (GR) effectors using cortisol-detecting sensor cells","volume":"22","author":"Ryu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.06.005_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113218","article-title":"Novel assays monitoring direct glucocorticoid receptor protein activity exhibit high predictive power for ligand activity on endogenous gene targets","volume":"152","author":"Van Moortel","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tips.2025.06.005_bb0145","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.1080\/07391102.2022.2123392","article-title":"Structure-based virtual screening, molecular docking, molecular dynamics simulation and MM\/PBSA calculations towards identification of steroidal and non-steroidal selective glucocorticoid receptor modulators","volume":"41","author":"Zare","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.tips.2025.06.005_bb0150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tibs.2024.01.012","article-title":"Glucocorticoid receptor signaling: intricacies and therapeutic opportunities","volume":"49","author":"Clarisse","year":"2024","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.tips.2025.06.005_bb0155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1096\/fj.01-0245com","article-title":"Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells","volume":"16","author":"Galon","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2025.06.005_bb0160","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1210\/endrev\/bnae008","article-title":"The glucocorticoid receptor: Isoforms, functions, and contribution to glucocorticoid sensitivity","volume":"45","author":"Lockett","year":"2024","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tips.2025.06.005_bb0165","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.molcel.2021.12.035","article-title":"Multimodal regulatory elements within a hormone-specific super enhancer control a heterogeneous transcriptional response","volume":"82","author":"Hoffman","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.06.005_bb0170","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3389\/fimmu.2019.01545","article-title":"A general introduction to glucocorticoid biology","volume":"10","author":"Timmermans","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2025.06.005_bb0175","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tips.2025.06.005_bb0180","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3390\/cells11040683","article-title":"Dimerization of the glucocorticoid receptor and its importance in (patho)physiology: a primer","volume":"11","author":"Timmermans","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.tips.2025.06.005_bb0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41577-020-00464-0","article-title":"Glucocorticoids in T cell development, differentiation and function","volume":"21","author":"Taves","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2025.06.005_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112389","article-title":"The impact of mineralocorticoid and glucocorticoid receptor interaction on corticosteroid transcriptional outcomes","volume":"594","author":"Alvarez de la Rosa","year":"2024","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tips.2025.06.005_bb0195","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/ijms22020623","article-title":"Molecular mechanisms of glucocorticoid-induced insulin resistance","volume":"22","author":"Beaupere","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.06.005_bb0200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ecl.2013.10.005","article-title":"Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism","volume":"43","author":"Geer","year":"2014","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.tips.2025.06.005_bb0205","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/s41467-023-37831-z","article-title":"Glucocorticoid activation of anti-inflammatory macrophages protects against insulin resistance","volume":"14","author":"Caratti","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.06.005_bb0210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/OARRR.S282606","article-title":"Understanding and managing corticosteroid-induced osteoporosis","volume":"13","author":"Kobza","year":"2021","journal-title":"Open Access Rheumatol."},{"key":"10.1016\/j.tips.2025.06.005_bb0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-006-0019-1","article-title":"The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis","volume":"79","author":"van Staa","year":"2006","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.tips.2025.06.005_bb0220","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(20)30636-X","article-title":"Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial","volume":"396","author":"Burmester","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2025.06.005_bb0225","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41584-024-01120-w","article-title":"Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases","volume":"20","author":"Buttgereit","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tips.2025.06.005_bb0230","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","article-title":"Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density","volume":"147","author":"Jia","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.tips.2025.06.005_bb0235","first-page":"S37","article-title":"Glucocorticoids and the osteoclast","volume":"33","author":"Teitelbaum","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.tips.2025.06.005_bb0240","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1359\/JBMR.041233","article-title":"Influence of glucocorticoids on human osteoclast generation and activity","volume":"20","author":"Sivagurunathan","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tips.2025.06.005_bb0245","doi-asserted-by":"crossref","first-page":"E587","DOI":"10.1152\/ajpendo.00219.2016","article-title":"Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice","volume":"311","author":"Piemontese","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2025.06.005_bb0250","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6910312","article-title":"RANKL\/RANK\/OPG pathway: a mechanism involved in exercise-induced bone remodeling","volume":"2020","author":"Tobeiha","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tips.2025.06.005_bb0255","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.tips.2025.06.005_bb0260","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cytogfr.2023.03.002","article-title":"Pathogenic mechanisms of glucocorticoid-induced osteoporosis","volume":"70","author":"Chen","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.tips.2025.06.005_bb0265","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S8756-3282(01)00610-X","article-title":"Molecular mechanisms of glucocorticoid-induced osteoporosis","volume":"29","author":"Patschan","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.tips.2025.06.005_bb0270","doi-asserted-by":"crossref","first-page":"E299","DOI":"10.1152\/ajpendo.00232.2005","article-title":"Glucocorticoids differentially regulate expression of duodenal and renal calbindin-D9k through glucocorticoid receptor-mediated pathway in mouse model","volume":"290","author":"Lee","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2025.06.005_bb0275","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2025.06.005_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.835720","article-title":"Bad to the bone: the effects of therapeutic glucocorticoids on osteoblasts and osteocytes","volume":"13","author":"Gado","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tips.2025.06.005_bb0285","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1172\/JCI68049","article-title":"FOXOs attenuate bone formation by suppressing Wnt signaling","volume":"123","author":"Iyer","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2025.06.005_bb0290","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/art.23454","article-title":"Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice","volume":"58","author":"Yao","year":"2008","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2025.06.005_bb0295","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2010.05.005","article-title":"Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor","volume":"11","author":"Rauch","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2025.06.005_bb0300","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1096\/fj.10-173393","article-title":"An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation","volume":"25","author":"Rauch","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2025.06.005_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115843","article-title":"Leukemia inhibitory factor treatment attenuates the detrimental effects of glucocorticoids on bone in mice","volume":"145","author":"Lee","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.tips.2025.06.005_bb0310","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/jbmr.3987","article-title":"Glucocorticoids disrupt skeletal angiogenesis through transrepression of NF-\u03baB-mediated preosteoclast PDGFB transcription in young mice","volume":"35","author":"Peng","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tips.2025.06.005_bb0315","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202301525","article-title":"Comparison of the glucocorticoid receptor binding and agonist activities of typical glucocorticoids: insights into their endocrine disrupting effects","volume":"21","author":"Liang","year":"2024","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.tips.2025.06.005_bb0320","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1021\/acs.jmedchem.7b01690","article-title":"Discovery of a novel oral glucocorticoid receptor modulator (AZD9567) with improved side effect profile","volume":"61","author":"Ripa","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.06.005_bb0325","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3390\/molecules29071546","article-title":"Channel expansion in the ligand-binding domain of the glucocorticoid receptor contributes to the activity of highly potent glucocorticoid analogues","volume":"29","author":"Seaton","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.tips.2025.06.005_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114382","article-title":"Discovery of novel non-steroidal selective glucocorticoid receptor modulators by structure- and IGN-based virtual screening, structural optimization, and biological evaluation","volume":"237","author":"Hu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2025.06.005_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202102435","article-title":"Discovery of novel GR ligands toward druggable GR antagonist conformations identified by MD simulations and markov state model analysis","volume":"9","author":"Hu","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.tips.2025.06.005_bb0340","doi-asserted-by":"crossref","first-page":"15710","DOI":"10.1021\/acs.jmedchem.2c01082","article-title":"Discovery and optimization of N-Acyl-6-sulfonamide-tetrahydroquinoline derivatives as novel non-steroidal selective glucocorticoid receptor modulators","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.06.005_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176901","article-title":"Protopanaxadiol derivative: a plant origin of novel selective glucocorticoid receptor modulator with anti-inflammatory effect","volume":"983","author":"Li","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2025.06.005_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1542351","article-title":"Novel selective glucocorticoid receptor modulator GRM-01 demonstrates dissociation of anti-inflammatory effects from adverse effects on glucose and bone metabolism","volume":"16","author":"Jakob","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2025.06.005_bb0355","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201800186","article-title":"Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy","volume":"2","author":"Heier","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.tips.2025.06.005_bb0360","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1210\/en.2010-1447","article-title":"The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation","volume":"152","author":"Hu","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.tips.2025.06.005_bb0365","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/bph.15957","article-title":"A plant-derived glucocorticoid receptor modulator with potency to attenuate the side effects of glucocorticoid therapy","volume":"180","author":"Wang","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2025.06.005_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2023.130831","article-title":"PFO5DoDA disrupts hepatic homeostasis primarily through glucocorticoid signaling inhibition","volume":"447","author":"Wang","year":"2023","journal-title":"J. Hazard. Mater."},{"key":"10.1016\/j.tips.2025.06.005_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000889","article-title":"Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study","volume":"5","author":"Buttgereit","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.tips.2025.06.005_bb0380","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/1756-185X.13053","article-title":"Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a phase 2 randomized study","volume":"20","author":"Stock","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.tips.2025.06.005_bb0385","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/cts.13624","article-title":"AZD9567 versus prednisolone in patients with active rheumatoid arthritis: a phase IIa, randomized, double-blind, efficacy, and safety study","volume":"16","author":"van Laar","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.tips.2025.06.005_bb0390","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/bcp.16082","article-title":"The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: results from a phase 2a clinical trial","volume":"90","author":"Ambery","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2025.06.005_bb0395","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S2665-9913(19)30103-1","article-title":"Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials","volume":"2","author":"Hegelund Myrback","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.tips.2025.06.005_bb0400","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1210\/mend.11.9.9979","article-title":"Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo","volume":"11","author":"Vayssi\u00e8re","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.tips.2025.06.005_bb0405","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.steroids.2018.02.010","article-title":"Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes","volume":"134","author":"Hoffman","year":"2018","journal-title":"Steroids"},{"key":"10.1016\/j.tips.2025.06.005_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107161","article-title":"Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice","volume":"26","author":"McCormack","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.tips.2025.06.005_bb0415","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/bph.16285","article-title":"5\u03b1-Tetrahydrocorticosterone: a topical anti-inflammatory glucocorticoid with an improved therapeutic index in a murine model of dermatitis","volume":"181","author":"Livingstone","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2025.06.005_bb0420","doi-asserted-by":"crossref","first-page":"15893","DOI":"10.1021\/acs.jmedchem.2c01579","article-title":"Discovery of ABBV-3373, an anti-TNF glucocorticoid receptor modulator immunology antibody drug conjugate","volume":"65","author":"Hobson","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.06.005_bb0425","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1021\/acs.jmedchem.3c01174","article-title":"Discovery of ABBV-154, an anti-TNF glucocorticoid receptor modulator immunology antibody-drug conjugate (iADC)","volume":"66","author":"Hobson","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.06.005_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add8936","article-title":"An anti-TNF-glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases","volume":"16","author":"McPherson","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2025.06.005_bb0435","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.42415","volume":"75","author":"Buttgereit","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2025.06.005_bb0440","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ard-2023-225371","article-title":"Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases","volume":"83","author":"Eiers","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2025.06.005_bb0445","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1002\/1873-3468.14409","article-title":"How to tame your genes: mechanisms of inflammatory gene repression by glucocorticoids","volume":"596","author":"Strickland","year":"2022","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tips.2025.06.005_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115145","article-title":"Biased regulation of glucocorticoid receptors signaling","volume":"165","author":"Mao","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tips.2025.06.005_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15549-5","article-title":"Site-specific phosphorylation regulates the structure and function of an intrinsically disordered domain of the glucocorticoid receptor","volume":"7","author":"Khan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.06.005_bb0460","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/MCB.00552-09","article-title":"Site-specific phosphorylation induces functionally active conformation in the intrinsically disordered N-terminal activation function (AF1) domain of the glucocorticoid receptor","volume":"30","author":"Garza","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tips.2025.06.005_bb0465","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1084\/jem.20180595","article-title":"Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses","volume":"216","author":"Franco","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tips.2025.06.005_bb0470","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nsmb.2456","article-title":"The structural basis of direct glucocorticoid-mediated transrepression","volume":"20","author":"Hudson","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.tips.2025.06.005_bb0475","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.molcel.2012.10.013","article-title":"Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes","volume":"49","author":"Uhlenhaut","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.06.005_bb0480","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41467-021-22234-9","article-title":"Genome-wide binding potential and regulatory activity of the glucocorticoid receptor's monomeric and dimeric forms","volume":"12","author":"Johnson","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.06.005_bb0485","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejphar.2017.03.057","article-title":"JTP-117968, a novel selective glucocorticoid receptor modulator, exhibits improved transrepression\/transactivation dissociation","volume":"803","author":"Kurimoto","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2025.06.005_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173880","article-title":"JTP-117968, a novel selective glucocorticoid receptor modulator, exhibits significant anti-inflammatory effect while maintaining bone mineral density in mice","volume":"895","author":"Kurimoto","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2025.06.005_bb0495","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1038\/s41598-024-58546-1","article-title":"Characterization of a new selective glucocorticoid receptor modulator with anorexigenic activity","volume":"14","author":"Lee","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.06.005_bb0500","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.3390\/ijms25168904","article-title":"Synthesis and anti-cancer activity of the novel selective glucocorticoid receptor agonists of the phenylethanolamine series","volume":"25","author":"Zhidkova","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.06.005_bb0505","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1021\/jo400079z","article-title":"Development of a large scale asymmetric synthesis of the glucocorticoid agonist BI 653048 BS H3PO4","volume":"78","author":"Reeves","year":"2013","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.tips.2025.06.005_bb0510","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/j.1476-5381.2011.01465.x","article-title":"5\u03b1-Reduced glucocorticoids exhibit dissociated anti-inflammatory and metabolic effects","volume":"164","author":"Yang","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2025.06.005_bb0515","doi-asserted-by":"crossref","first-page":"22908","DOI":"10.1074\/jbc.M402822200","article-title":"5alpha-reduced glucocorticoids, novel endogenous activators of the glucocorticoid receptor","volume":"279","author":"McInnes","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2025.06.005_bb0520","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semarthrit.2019.03.010","article-title":"Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus","volume":"49","author":"Deng","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.tips.2025.06.005_bb0525","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.addr.2019.02.004","article-title":"Chronopharmacology of glucocorticoids","volume":"151-152","author":"Scherholz","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tips.2025.06.005_bb0530","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jsbmb.2010.02.027","article-title":"Selective glucocorticoid receptor modulators","volume":"120","author":"De Bosscher","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725001233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725001233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:15:49Z","timestamp":1762251349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725001233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":106,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0165614725001233"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.06.005","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and development of glucocorticoid receptor modulators","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}